162
Participants
Start Date
May 5, 2022
Primary Completion Date
October 15, 2025
Study Completion Date
November 7, 2025
Relatlimab
Specified dose on specified days
Nivolumab
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0004, Hong Kong
Local Institution - 0043, District Taichung City
Local Institution - 0052, Rio Piedras
Local Institution - 0045, Camperdown
Local Institution - 0013, Melbourne
Local Institution - 0026, Heidelberg
Local Institution - 0022, Adelaide
Local Institution - 0017, Nedlands
Local Institution - 0046, Taipei
Local Institution - 0061, New York
Local Institution - 0062, The Bronx
Local Institution - 0049, Taipei
Local Institution - 0037, Seongnam-si
Local Institution - 0032, Santiago de Compostela
Local Institution - 0030, Washington D.C.
Local Institution - 0036, Milan
Local Institution - 0059, Baltimore
Local Institution - 0067, Madrid
Local Institution - 0053, Madrid
Local Institution - 0038, Pamplona
Local Institution - 0008, Rennes
Local Institution - 0003, Padua
Local Institution - 0012, Grenoble
Local Institution - 0007, Santander
Local Institution - 0051, Düsseldorf
Local Institution - 0024, Taichung
Local Institution - 0040, Zaragoza
Local Institution - 0002, Reims
Local Institution - 0033, Milwaukee
Local Institution - 0057, Mainz
Local Institution - 0035, Frankfurt
Local Institution - 0055, Munich
Local Institution - 0021, Avignon
Local Institution - 0042, Los Angeles
Local Institution - 0039, Los Angeles
Local Institution - 0054, Suresnes
Local Institution - 0034, San Francisco
Local Institution - 0029, Singapore
Local Institution - 0027, Singapore
Local Institution - 0018, Singapore
Local Institution - 0044, Singapore
Local Institution - 0064, Guangzhou
Local Institution - 0066, Xi'an
Local Institution - 0031, Shatin
Local Institution - 0050, Yokohama
Local Institution - 0047, Kashiwa-shi
Local Institution - 0041, Sayama
Local Institution - 0048, Matsuyama
Local Institution - 0058, Kanazawa
Local Institution - 0060, Boston
Local Institution - 0065, Boston
Local Institution - 0025, Edmonton
Local Institution - 0009, Toronto
Local Institution - 0001, Nice
Local Institution - 0010, Roma
Local Institution - 0063, Chuo-ku
Local Institution - 0028, Bydgoszcz
Local Institution - 0016, Warsaw
Local Institution - 0023, Gdansk
Local Institution - 0019, San Juan
Local Institution - 0056, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY